Offering biomedical innovators the experience, expertise, and funding required for success.
Through the RCT Ventures program, venture capital is provided to start-up or early-stage companies with technologies that have the potential to become significant biomedical products with a definite competitive edge. Learn more ›
RCT develops and invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics. Many of these life science tools are available from RCT through affordable nonexclusive licensing. Learn more ›
GEORGETOWN, TX, September 24, 2020 – DisperSol Technologies LLC announced today that its Board of Directors has appointed David S. Snyder as its Chief Financial Officer effective October 1, 2020. “David Snyder is a highly accomplished pharmaceutical finance executive with … Learn more